Advanced Cell Technology Announces Release of New Edition of Definitive Resource in Tissue Engineering
December 18 2013 - 8:30AM
Business Wire
Widely-recognized publication in tissue
engineering co-edited by ACT’s Chief Scientific Officer Robert
Lanza, M.D.
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in
the field of regenerative medicine, announced today that its chief
scientific officer, Robert Lanza, M.D., and Robert Langer, Sc.D.,
Koch Institute Professor at MIT and Scientific Chair of ACT’s Board
of Directors, have released the fourth edition of “Principles of
Tissue Engineering” (Academic Press/Elsevier), the
widely-recognized definitive resource in the field of tissue
engineering. The 1936-page volume includes contributions from 20
members of the National Academies of Science, Engineering, and
Institute of Medicine, as well as dozens of pioneers in the fields
of stem cells, tissue engineering, and regenerative medicine.
Principles of Tissue Engineering, Fourth Edition, follows three
very successful editions published since in 1997. The first edition
was the first comprehensive body of work dedicated entirely to the
tissue engineering field. The volume quickly became the most
relevant textbook in the tissue engineering arena. Now, 16 years
later, major advances have occurred, with entirely new classes of
stem cells being described. Progress in the field has been so
rapid, that since publication of the last edition of the book, the
first clinical trials have been carried out using human embryonic
stem cells (hESCs). Last year, the first paper reporting results of
patients treated with hESCs was published by ACT and its
collaborators.
The Fourth Edition of “Principles” covers all of this recent
progress as well as the latest advances in the biology and design
of tissues and organs, from mathematical models to clinical
reality. The book combines the prerequisites for a general
understanding of tissue growth and development, the tools needed to
design tissues and organs, as well as a presentation by the world’s
experts of what is currently known about each specific organ
system. “Principles” strikes a balance among the diversity of
subjects that are related to tissue engineering, including biology,
chemistry, and engineering, while also emphasizing those research
areas that are likely to be of clinical value in the future. This
new edition includes greatly expanded focus on stem cells,
including iPS cells and stem cell niches. This up-to-date coverage
of stem cell biology and other emerging technologies is
complemented by a series of new chapters on recent clinical
experience in applying tissue engineering, as well as a new section
on the application of tissue-engineering for food production. The
result is a comprehensive textbook that should be useful to
students and experts alike.
In addition to Drs. Lanza and Langer, Principles 4E was
co-edited by Joseph Vacanti, M.D., John Homans Professor of Surgery
and Director, Laboratory for Tissue engineering and Organ
Fabrication at Harvard Medical School and Massachusetts General
Hospital.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company
applying cellular technology in the field of regenerative medicine.
For more information, visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and
operating results, the relevance and applicability of clinical
trials in animals to studying the effect of products in humans,
future growth in animal and human research and development
programs, potential new applications of and expanded indications
covering our technology, the effects of donorless sources of stem
cells on potency and the risk of communicable diseases in the
manufacturing context, the existence and size of potential or
existing market opportunities for the company, the effect of the
company’s products on the medical needs and quality of life of
pets, and any other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements
that are not statements of historical fact (including statements
containing the words “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates,” and similar expressions) should also be
considered to be forward-looking statements. There are a number of
important factors that could cause actual results or events to
differ materially from those indicated by such forward-looking
statements, including: limited operating history, need for and
limited sources of future capital, failures or delays in obtaining
regulatory approval of products, risks inherent in the development
and commercialization of potential products, reliance on new and
unproven technology in the development of products, protection of
our intellectual property, and economic conditions generally.
Additional information on potential factors that could affect our
results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the Quarterly
Report on Form 10-Q for the three months ended June 30, 2013.
Forward-looking statements are based on the beliefs, opinions, and
expectations of the company’s management at the time they are made,
and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions,
expectations, or other circumstances should change. Forward-looking
statements are based on the beliefs, opinions, and expectations of
the company’s management at the time they are made, and the company
does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the
Company’s clinical trials will be successful.
Investors:CEOcast, Inc.James Young, 212-732-4300orPress:Russo
PartnersDavid Schull, 212-845-4271